Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thanh H Dellinger

Showing results (1-10 of 44) with videos related to

Pageof 5
Sort By:
Expert Review of Anticancer Therapy|July 11, 2009
Systemic therapy for recurrent endometrial cancer: a review of North American trialsThanh H Dellinger, Bradley J Monk
Journal of Minimally Invasive Gynecology|October 31, 2016
Comprehensive Staging of Uterine Carcinosarcoma Using a Multiquadrant Robotic PlatformThanh H Dellinger, Mark T Wakabayashi, Ernest S Han
Journal of the National Comprehensive Cancer Network : JNCCN|February 14, 2018
Secondary Neoplasms of the Female Lower Genital Tract After Hematopoietic Cell TransplantationHoward A Chang, Saro H Armenian, Thanh H Dellinger
Expert Review of Anticancer Therapy|December 14, 2011
Role of canonical Wnt signaling in endometrial carcinogenesisThanh H Dellinger, Kestutis Planutis, Krishnansu S Tewari, et al.
Journal of Clinical Medicine|June 10, 2023
Complete Pathologic Response to PARP Inhibitor Olaparib in a Patient with Stage IVB Recurrent Endometrioid Endometrial AdenocarcinomaRosemary Noel Senguttuvan, Christina Wei, Mustafa Raoof, et al.
Journal of Clinical Medicine|January 8, 2025
Single-Cell Transcriptomics Sheds Light on Tumor Evolution: Perspectives from City of Hope's Clinical Trial TeamsPatrick A Cosgrove, Andrea H Bild, Thanh H Dellinger, et al.
Gynecologic Oncology|February 11, 2016
L1CAM is an independent predictor of poor survival in endometrial cancer - An analysis of The Cancer Genome Atlas (TCGA)Thanh H Dellinger, David D Smith, Ching Ouyang, et al.
BMC Cancer|March 12, 2017
Disruption of TWIST1-RELA binding by mutation and competitive inhibition to validate the TWIST1 WR domain as a therapeutic targetCai M Roberts, Sophia A Shahin, Joana Loeza, et al.
Oncotarget|June 1, 2018
Ruxolitinib synergistically enhances the anti-tumor activity of paclitaxel in human ovarian cancerErnest S Han, Wei Wen, Thanh H Dellinger, et al.
Scientific Reports|October 8, 2017
Pterostilbene, a natural phenolic compound, synergizes the antineoplastic effects of megestrol acetate in endometrial cancerWei Wen, Gina Lowe, Cai M Roberts, et al.
Pageof 5

Showing results (1-10 of 44) with videos related to

Sort By:
Pageof 5
Expert Review of Anticancer Therapy|July 11, 2009
Systemic therapy for recurrent endometrial cancer: a review of North American trialsThanh H Dellinger, Bradley J Monk
Journal of Minimally Invasive Gynecology|October 31, 2016
Comprehensive Staging of Uterine Carcinosarcoma Using a Multiquadrant Robotic PlatformThanh H Dellinger, Mark T Wakabayashi, Ernest S Han
Journal of the National Comprehensive Cancer Network : JNCCN|February 14, 2018
Secondary Neoplasms of the Female Lower Genital Tract After Hematopoietic Cell TransplantationHoward A Chang, Saro H Armenian, Thanh H Dellinger
Expert Review of Anticancer Therapy|December 14, 2011
Role of canonical Wnt signaling in endometrial carcinogenesisThanh H Dellinger, Kestutis Planutis, Krishnansu S Tewari, et al.
Journal of Clinical Medicine|June 10, 2023
Complete Pathologic Response to PARP Inhibitor Olaparib in a Patient with Stage IVB Recurrent Endometrioid Endometrial AdenocarcinomaRosemary Noel Senguttuvan, Christina Wei, Mustafa Raoof, et al.
Journal of Clinical Medicine|January 8, 2025
Single-Cell Transcriptomics Sheds Light on Tumor Evolution: Perspectives from City of Hope's Clinical Trial TeamsPatrick A Cosgrove, Andrea H Bild, Thanh H Dellinger, et al.
Gynecologic Oncology|February 11, 2016
L1CAM is an independent predictor of poor survival in endometrial cancer - An analysis of The Cancer Genome Atlas (TCGA)Thanh H Dellinger, David D Smith, Ching Ouyang, et al.
BMC Cancer|March 12, 2017
Disruption of TWIST1-RELA binding by mutation and competitive inhibition to validate the TWIST1 WR domain as a therapeutic targetCai M Roberts, Sophia A Shahin, Joana Loeza, et al.
Oncotarget|June 1, 2018
Ruxolitinib synergistically enhances the anti-tumor activity of paclitaxel in human ovarian cancerErnest S Han, Wei Wen, Thanh H Dellinger, et al.
Scientific Reports|October 8, 2017
Pterostilbene, a natural phenolic compound, synergizes the antineoplastic effects of megestrol acetate in endometrial cancerWei Wen, Gina Lowe, Cai M Roberts, et al.
Pageof 5